Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,624 across all filing types
Latest filing 2023-03-16 Regulatory Filings
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT-NMPA APPROVES IND APPLICATIONS FOR DISITAMAB VEDOTIN FOR INJECTION IN COMBINATION WITH TORIPALIMAB OR LETROZOLE AND DISITAMAB VEDOTIN WITH PERTUZUMAB IN COMBINATION WITH OR WITH
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by RemeGen Co., Ltd. regarding the approval by the National Medical Products Administration (NMPA) of Investigational New Drug (IND) applications for certain therapies. It is an announcement of regulatory approval and clinical trial initiation, not a financial report, earnings release, or management discussion. The document is about regulatory and clinical development updates, which do not fit into financial report categories. It is not a report publication announcement since it contains substantive content about the approvals. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories such as legal proceedings or capital updates.
2023-03-16 English
VOLUNTARY ANNOUNCEMENT-NMPA APPROVES IND APPLICATION FOR RC88 FOR INJECTION IN COMBINATION WITH TORIPALIMAB FOR PATIENTS WITH ADVANCED MALIGNANT SOLID TUMOURS
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by RemeGen Co., Ltd. regarding the approval by the National Medical Products Administration (NMPA) of an Investigational New Drug (IND) application for a drug candidate (RC88) in combination with another drug for treating advanced malignant solid tumors. The content focuses on regulatory approval and clinical study initiation rather than financial results, management changes, or shareholder votes. The document is relatively short (3137 characters) and serves as a regulatory update or announcement rather than a detailed report or financial filing. It does not contain financial data, management discussion, or meeting materials. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2023-03-16 English
Monthly Return of Equity Issuer on Movement in Securities for the month ended 28 February 2023
Regulatory Filings Classification · 95% confidence The document is a monthly return report submitted to the Hong Kong Exchanges and Clearing Limited regarding movements in securities, specifically focusing on authorized and issued shares of Overseas Chinese Town (Asia) Holdings Limited for the month ended 28 February 2023. It details share capital, issued shares, and confirms compliance with listing rules. The document is regulatory in nature, reporting share capital and share issuance movements, but it is not a full financial report, earnings release, or management discussion. It is also not a proxy, AGM material, or legal proceeding. The document fits the description of a Regulatory Filing (RNS) as it is a compliance report submitted to the exchange about share capital movements and confirmations, without substantive financial statements or detailed analysis. The length and content confirm it is not a brief announcement or a report publication notice but a formal regulatory submission.
2023-03-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2023
Share Issue/Capital Change Classification · 100% confidence The document is a detailed monthly return on movements in securities, specifically focusing on authorized and issued share capital, share options, convertibles, and other share-related movements for RemeGen Co., Ltd. It includes confirmations related to securities issuance and compliance with listing rules. The document is submitted to the Hong Kong Exchanges and Clearing Limited and references specific listing rules (Chapter 19B, Main Board Rule 13.25A / GEM Rule 17.27A). The content is focused on share capital and share issuance movements rather than financial results, management changes, or legal matters. This matches the description of a Share Issue/Capital Change filing, which covers announcements regarding new share issues, stock splits, or other capital changes. The document length (8300 characters) and detailed data confirm it is the report itself, not just an announcement of a report. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2023-03-02 English
INSIDE INFORMATION-2022 ANNUAL RESULTS UPDATE ANNOUNCEMENT
Earnings Release Classification · 95% confidence The document is titled '2022 Annual Results Update Announcement' and contains key financial information for the year 2022, including operating revenue, profit/loss, and asset figures. It explicitly states that the financial data is preliminary, unaudited, and that the final audited data will be disclosed in the Company's 2022 annual report. The document is an announcement of preliminary annual results rather than the full annual report itself. It is also over 7,000 characters, indicating it is not a brief notice but a detailed announcement. The document references regulatory rules for disclosure and inside information provisions, consistent with a financial results announcement. Given these factors, the document fits best as an Earnings Release (ER), which is the initial announcement of annual financial results with key highlights but not the full audited report. FY 2022
2023-02-27 English
PROFIT WARNING
Earnings Release Classification · 95% confidence The document is titled 'PROFIT WARNING' and is an announcement made pursuant to the Listing Rules of the Hong Kong Stock Exchange. It provides a preliminary assessment of the unaudited consolidated management accounts for the year ended 31 December 2022, indicating an expected loss range and reasons for the loss increase. It explicitly states that the financial results are not finalized, audited, or reviewed and that the full annual results announcement will be published later. The document is short (4860 characters) and serves as an early alert to shareholders and investors about expected financial performance, not a full financial report. This fits the profile of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results highlighting key points before the full report is issued. FY 2022
2023-02-15 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.